Skip to content

Study · Randomized controlled trial · 2015

7 results

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G

The Journal of clinical endocrinology and metabolism13 Nov 2014Cited by 193 (Europe PMC)

PMID25393645 (opens in a new tab)DOI10.1210/jc.2014-3718 (opens in a new tab)PepBankPUB-25393645
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, lumbar spine BMD increased by 5.2% with abaloparatide, significantly more than placebo.

    In plain wordsIn women, abaloparatide increased lumbar spine bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    5.2%
    abaloparatide 40 μg
    BMD change
    1.6%
    placebo lumbar spine

    Source sentences

    Summary
    At 24 weeks, lumbar spine BMD increased by 2.9, 5.2, and 6.7% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 5.5% in the teriparatide group.
    3 context sentences
    Summary · context
    The increases in the 40- and 80-μg abaloparatide groups and the teriparatide group were significantly greater than placebo (1.6%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, lumbar spine BMD increased by 6.7% with abaloparatide, significantly more than placebo.

    In plain wordsIn women, abaloparatide increased lumbar spine bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    6.7%
    abaloparatide 80 μg
    BMD change
    1.6%
    placebo lumbar spine

    Source sentences

    Summary
    At 24 weeks, lumbar spine BMD increased by 2.9, 5.2, and 6.7% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 5.5% in the teriparatide group.
    3 context sentences
    Summary · context
    The increases in the 40- and 80-μg abaloparatide groups and the teriparatide group were significantly greater than placebo (1.6%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, femoral neck BMD increased by 3.1% with abaloparatide, significantly more than placebo.

    In plain wordsIn women, abaloparatide increased femoral neck bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    3.1%
    abaloparatide 80 μg
    BMD change
    0.8%
    placebo femoral neck

    Source sentences

    Summary
    Femoral neck BMD increased by 2.7, 2.2, and 3.1% in abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 1.1% in the teriparatide group.
    3 context sentences
    Summary · context
    The increase in femoral neck BMD with abaloparatide, 80 μg was significantly greater than placebo (0.8%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, total hip BMD increased by 2.0% with abaloparatide, more than placebo.

    In plain wordsIn women, abaloparatide increased total hip bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    2%
    abaloparatide 40 μg
    BMD change
    0.4%
    placebo total hip

    Source sentences

    Summary
    Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively.
    3 context sentences
    Summary · context
    The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, total hip BMD increased by 2.0% with abaloparatide, more than teriparatide.

    In plain wordsIn women, abaloparatide increased total hip bone density more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    2%
    abaloparatide 40 μg
    BMD change
    0.5%
    teriparatide 20 μg total hip

    Source sentences

    Summary
    Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively.
    3 context sentences
    Summary · context
    The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, total hip BMD increased by 2.6% with abaloparatide, more than placebo.

    In plain wordsIn women, abaloparatide increased total hip bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    2.6%
    abaloparatide 80 μg
    BMD change
    0.4%
    placebo total hip

    Source sentences

    Summary
    Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively.
    3 context sentences
    Summary · context
    The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, total hip BMD increased by 2.6% with abaloparatide, more than teriparatide.

    In plain wordsIn women, abaloparatide increased total hip bone density more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg daily · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMD change
    2.6%
    abaloparatide 80 μg
    BMD change
    0.5%
    teriparatide 20 μg total hip

    Source sentences

    Summary
    Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively.
    3 context sentences
    Summary · context
    The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%).
    Summary · context
    Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg.
    Summary · context
    Postmenopausal women with osteoporosis (n = 222).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT04467983

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Hospital for Special Surgery, New Yorkn = 701 Feb 2021 to est. 31 Dec 2026

Osteoporosis, Postmenopausal

Trial pageClinicalTrials.govUpdated 13 Oct 2026
CompletedPhase 2Results postedNCT00542425

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Radius Health, Inc.n = 222Apr 2007 to Jun 2009

Osteoporosis

Trial pageClinicalTrials.govUpdated 30 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.